The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics
authors
keywords
- Reimbursement
- Regenerative medicine
- Valuation
- Publications
- Trade organisations
- Orphan drugs
- Risk-sharing agreements
document type
ARTabstract
Structured Abstract Aims This paper aims to map the trends and analyse key institutional dynamics that are constituting the policies for reimbursement of Regenerative Medicine (RM), especially in the UK. Materials & Methods Two quantitative publications studies using Google Scholar and a qualitative study based on a larger study of 43 semi-structured interviews. Results Reimbursement has been a growing topic of publications specific to RM and independent from orphan drugs. Risk-sharing schemes receive attention amongst others for dealing with RM reimbursement. Trade organisations have been especially involved on RM reimbursement issues and have proposed solutions. Conclusion The policy and institutional landscape of reimbursement studies in RM is a highly variegated and conflictual one and in its infancy.
